AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01102816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized acupuncture treatment
Description: Individualized acupuncture treatment which focuses on each patient's symptoms and conditions will be provided twice a week for 6 weeks on a non-dialysis access day or before hemodialysis at dialysis-access day. 10-20 acupuncture needles will be inserted on the body except the arteriovenous fistula-located arm(s). Electrical stimulation of acupuncture will be conducted on 4 needles and the remained needles will be manipulated manually to elicit de-qi sensation. Needle retention time will be 20 minutes.~Routine care provided by dialysis staffs, primary physicians and other healthcare providers will be maintained.~Patients who received acupuncture treatment will be interviewed to explore patient's perceptions and experiences of acupuncture for their pain management. (Nested-qualitative study)
Study NCT01102816 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Routine care
Description: Patients in this group will maintain routine care provided by their dialysis staffs, primary physicians or other healthcare providers for symptomatic care and disease management of end-stage renal disease through 6 weeks. After post-treatment evaluation, acupuncture treatment will be provided to patients who want to receive acupuncture treatment.
Study NCT00852124 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3
Description: VSL#3 2 times daily
Study NCT01342757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT01342757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally
Study NCT01342757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance spectroscopic imaging
Description: Undergo MRI
Study NCT01342757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies
Study NCT02548390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXDX-107
Description: Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined. An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed. Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
Study NCT04573114 — intervention group
Intervention type: PROCEDURE
Intervention: Verticalization
Description: Progressive levels of verticalization
Study NCT03353883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin SR
Description: GnRH agonist depot( Decapeptyl) will be taken in the previous mid luteal cycle in group A and the first day in group B
Study NCT00235391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 125 mg, 250 mg and 500 mg tablets. Dosage was calculated based on participant's body weight. Tablets were dispersed in water, orange or apple juice and taken orally once a day.
Study NCT02845947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: The music therapy intervention offered during the time of the patient's extubation readiness trial (ERT) will consist of live music using a multitude of instruments and patient-preferred and improvised music. The music therapy interventions will always include the use of live music, including guitar, keyboard, voice, ocean drum, reverie harp, and/or various percussive instruments. The music therapist will use a tablet to understand how to play patient-preferred songs. To ensure patient safety, the music therapist will adhere to the infection control policies set forth by the institution. The following are the intended goals of the Music therapy intervention: facilitating relaxation, alleviation of anxiety, and successful utilization of new coping skills.
Study NCT03282773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deferred stent implantation
Description: Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted 4-10 days after restoration of blood flow in left main coronary artery in a secondary PCI.
Study NCT03282773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate stent implantation
Description: Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted immediately after restoration of blood flow in left main coronary artery in a secondary PCI.
Study NCT03171246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Solid food-based intervention
Description: Individually tailored energy content according to age/activity
Study NCT04258995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)
Description: 2 formulations at 1 dose level
Study NCT02372552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CROMA
Description: Microwave coagulation of small blood vessels
Study NCT03000777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin plus zinc
Description: Melatonin 1 mg plus Zinc 10 mg o.d. 1 hour before going to bed during 16 weeks
Study NCT03000777 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isomaltose o.d. 1 hour before going to bed during 16 weeks
Study NCT04092192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVC filter removal
Description: In the clinic, it will be explained to patient that they are asked to participate in a study that would randomize them to one of two established techniques for IVC filter removal. It will be explained these are both techniques that are used by interventional radiologists normally used for IVC filter retrieval.~One technique would be the utilization of an endovascular snare (like a lasso) device that is designed to catch the hook of the filter and allow it to be captured.~The other technique described will be the usage of a rigid forceps device that will be used to engage the filter apex directly and allow for the filter to be capture/removed.
Study NCT03000504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ballooned intercostal drain
Description: Patients will have a Rocket Medical 16F ballooned intercostal drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
Study NCT03000504 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ballooned intercostal drain
Description: Patients will have a Rocket Medical 16F ballooned intercostal drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
Study NCT00970450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol 1 g i.v. once
Study NCT00970450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropisetron
Description: Tropisetron 5 mg i.v. once
Study NCT00970450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tropisetron
Description: Tropisetron 5 mg i.v. once
Study NCT00970450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT01982006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery with Phacoemulsification
Description: Each patients randomized in the phaco arm will undergo a conventional cataract surgery.~Corneal incisions will be manually performed using the same calibrated blade and at the same location for all procedures of one surgeon.~Phacoemulsification machine used to perform cataract surgery in each center will be the same for all patients included in the center. The IOL (IntraOcular Lens) used in each center will be the same for all patients treated in the center.
Study NCT01982006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery
Description: Each patients randomized in the femto arm will undergo a femtosecond laser assisted cataract surgery.~Corneal incisions will be performed by the laser. Number, size and location of the incisions must be the same than in the phaco arm for all patients treated by one surgeon.~Phacoemulsification machine used to remove the liquefied lens will be the same than in the phaco arm The IOL used in each center will be the same than in the phaco arm
Study NCT03597178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: ACUVUE OASYS® 1-DAY with HydraLuxe™ Technology
Study NCT03234556 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy of Prostate
Description: Undergo SR-Bx
Study NCT03234556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Prostate
Description: Undergo SR-Bx
Study NCT03234556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03234556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03234556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03234556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03234556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI Ultrasound Fusion Guided Biopsy
Description: Undergo MRUS-Bx
Study NCT03234556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI Ultrasound Fusion Guided Biopsy
Description: Undergo MRUS-Bx
Study NCT04510883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACO
Description: The intervention is a fully-automated web-based eHealth application in which two embodied conversational agents engage in dialogue with older adults in order to motivate them towards dietary behavior change and decrease loneliness. The application consists of five different modules, each one applying different behavior change techniques.
Study NCT04510883 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list + PACO
Description: Waiting list + PACO
Study NCT02793830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily reminders of taking medications
Description: Reminders. Participants will receive medication-taking reminders from the researcher. These reminders are sent through the mobile application-BB Reminder on an unencrypted external device (a phone borrowed from Duke University School of Nursing and is used specifically for this study by the researcher). BB Reminder has the function that after inputting a patient's phone number and prescriptions, participants can receive reminders through text messages of the name, dosage, function, and administration route for every dose of his/her medications. The daily reminders will be sent to participants 15 minutes before every dose of their medications.
Study NCT02793830 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: Educational materials. Participants will receive educational materials from the researcher. These educational materials will be sent through the mobile application-WeChat. The educational materials include short articles (\< 500 words) and/or pictures. They will be retrieved from the Chinese Cardiovascular Disease-Prevention Information Website (www.healthyheart-china.com), which is governed by the Chinese Ministry of Health. The validity of information from it is guaranteed. The retrieved educational materials will be screened by the cardiologist, the head nurse, and the researcher, before sending to participants. The educational materials will be sent to participants every other day at any time during 8 am and 10 pm.
Study NCT02793830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational materials
Description: Educational materials. Participants will receive educational materials from the researcher. These educational materials will be sent through the mobile application-WeChat. The educational materials include short articles (\< 500 words) and/or pictures. They will be retrieved from the Chinese Cardiovascular Disease-Prevention Information Website (www.healthyheart-china.com), which is governed by the Chinese Ministry of Health. The validity of information from it is guaranteed. The retrieved educational materials will be screened by the cardiologist, the head nurse, and the researcher, before sending to participants. The educational materials will be sent to participants every other day at any time during 8 am and 10 pm.
Study NCT03327376 — intervention group
Intervention type: DEVICE
Intervention: ultrasound-screening
Description: Daily ultrasound-screening for CVC-related thrombosis (DUCT) by compression ultrasound and color doppler ultrasound.
Study NCT01745523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Synthetic macromolecule HPC and trehalose
Description: Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
Study NCT01745523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SSS containing HSA and sucrose
Description: • Oocytes are vitrified using the SSS containing HSA and sucrose
Study NCT02488213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
Study NCT02488213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Diet Guidance
Description: The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
Study NCT01185964 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Olaratumab 15 mg/kg by intravenous transfusion (I.V.) on days 1+8 of a 21-day cycle
Study NCT01185964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
Study NCT01185964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
Study NCT00549029 — intervention group
Intervention type: GENETIC
Intervention: DNA
Description: withdraw 5\~10mL blood from vein only once during the whole design
Study NCT03054597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Circular light motion
Description: Exercise with circular light motion
Study NCT03054597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagonal light motion
Description: Exercise with diagonal light motion
Study NCT03054597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral light motion
Description: Exercise with peripheral light motion
Study NCT03054597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT02486991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunnel + AlloDerm®
Description: A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
Study NCT02486991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunnel + AlloDerm®
Description: A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
Study NCT02486991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunnel + AlloDerm® + Verticals
Description: The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
Study NCT00520013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00520013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Study NCT00520013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00520013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT04542460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: A loop recorder is implanted i all patients in both study groups to investigate:~* Prevalence and severity of cardiac arrhythmias.~* Effect on detected arrhythmia, in particular ventricular tachyarrhythmia, of optimal medical therapy vs. coronary revascularization by PCI.~* Prevalence and severity of cardiac arrhythmias in CTO-patients with failed PCI.~* Indication for prophylactic ICD implantation in CTO-patients treated conservatively or by PCI and after failed PCI.~* Relation of arrhythmias to angina pectoris symptoms (CCS class), Quality of life questionnaire results and presence of myocardial reversible perfusion defects by CMRI.
Study NCT02788201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 approved agents
Description: One or combination of agents: Abiraterone, Arsenic Trioxide, Asparaginase Escherichia coli source, Axitinib, Azacitidine, Bendamustine, Bleomycin, Bortezomib, Busulfan, Carboplatin, Carfilzomib, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Crizotinib, Cytarabine, Dacarbazine, Dactinomycin, Dasatinib, Daunorubicin, Decitabine, Docetaxel, Doxorubicin, Epirubicin, Eribulin, Erlotinib, Estramustine, Etoposide, Exemestane, Floxuridine, Fludarabine, Fluorouracil, Gefitinib, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Irinotecan, Ixabepilone, Lapatinib, Lomustine, Mechlor, Melphalan, Mercapto, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Nilotinib, Oxaliplatin, Paclitaxel, Pazopanib, Pentostatin, Romidepsin, Ruxolitinib, Sorafenib, Streptozocin, Sunitinib, Tamoxifen, Temsirolimus, Teniposide, Thioguanine, Thiotepa, Topotecan, Toremifene, Tretinoin, Vandetanib, Vemurafenib, Vinblastine, Vincristine, Vismodegib, and/or Vorinostat
Study NCT02788201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COXEN
Description: The CO eXpression ExtrapolatioN (COXEN) algorithm will be used to determine the next best therapy from among 75 Food and Drug Administration (FDA) approved agents (single agent or combination) in patients that have progressed on at least one chemotherapy regimen.
Study NCT01053559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: certolizumab pegol
Description: 400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter
Study NCT01852825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-8237
Description: A single tablet of MK-8237 with 12 DU, administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
Study NCT01852825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
Study NCT01852825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NAC
Description: 0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84
Study NCT01852825 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NAC
Description: 0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84
Study NCT02181478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
Study NCT01059786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilators
Description: Additional treatment with bronchodilators may be indicated.
Study NCT01059786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilators
Description: Additional treatment with bronchodilators may be indicated.
Study NCT02181478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given by IV during prep at 40mg/m2 for 5 days
Study NCT02181478 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1
Study NCT02181478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100
Study NCT02181478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.